Trevena announced results of TRV027 proof-of-concept study in COVID-19 patients
On Sept. 30, 2021, Trevena announced data from 30 patients enrolled in the proof-of-concept study of TRV027, the…
Biotechnology | Cartoons - Original | COVID-19 | Diagnostics | Medical Device | Neurology | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 vaccinated vs. non-vaccinated
This cartoon illustrates the various issues facing individuals across the U.S. who are vaccinated against COVID-19 verus those…
Colossal, a de-extinction company was founded to bring the Woolly Mammoth back to life
On Sept. 29, 2021, Colossal, a de-extinction company that is combining the science of genetics with the business…
NEJM published positive phase 3 trial resulted for REGEN-COV (casirivimab and imdevimab) to treat COVID-19
On Sept. 29, 2021, Regeneron announced that the New England Journal of Medicine (NEJM) published positive detailed results…
Pfizer reported positive top-line results of phase 3 study exploring coadministration of Prevnar 20 With seasonal Flu vaccine
On Sept. 29, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…
Phase II/III trial showed Ronapreve (casirivimab and imdevimab) significantly reduced viral load in patients hospitalised with COVID-19
On Sept. 29, 2021, Roche confirmed positive data from the phase II/III 2066 study, investigating Ronapreveﾙ (casirivimab and…
2022 Breakthrough Prize in Life Sciences awarded to Penn Medicine mRNA pioneers Drew Weissman and Katalin Karik
On Sept. 29, 2021, the University of Pennsylvania announced that the Breakthrough Prize in Life Sciences was awarded…
VBI Vaccines announced preclinical data and Initiation of VBI-2905 clinical trial targeting broadened immunity against COVID-19
On Sept. 29, 2021, VBI Vaccines announced positive results from multiple preclinical studies against several COVID-19 variants of…
Cepheid received Emergency Use Authorization For SARS-CoV-2, Flu A, Flu B and RSV combination test
On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
University of Missouri researchers identified mutations of Delta, Delta Plus variants
On Sept. 28, 2021, the University of Missouri researcher Kamlendra Singh led a team that analyzed protein sequences…
AIM ImmunoTech submitted pre-IND application to FDA for phase 2 clinical studies of Ampligen as potential therapeutic for COVID-19
On Sept. 28, 2021, AIM ImmunoTech announced that is had submitted a Pre-Investigational New Drug application (Pre-IND) to…
Sanofi terminated mRNA COVID-19 vaccine development to focus on recombinant vaccine candidate
On Sept. 28, 2021, Sanofi announced that it had terminated plans for its own mRNA-based COVID-19 vaccine given…
Over half of U.S. children have detectable levels of lead in their blood in Quest Diagnostics study published in JAMA
On Sept. 28, 2021, Quest Diagnostics reported that one in two (50.5%) American children under six years of…
Pfizer and BioNTech submitted initial data to FDA from pivotal trial of COVID-19 vaccine in children 5 to <12 years of age
On Sept. 28, 2021, Pfizer and BioNTech announced they had submitted data to the U.S. Food and Drug…
Soligenix announced publication demonstrating efficacy and broad neutralizing activity of its COVID-19 Vaccine
On Sept. 28, 2021, Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program)…
TGen part of $60 million grant awarded to UArizona to create national Precision Aging Network
On Sept. 28, 2021, TGen, an affiliate of City of Hope, will use its MindCrowd website portal to…
NIAID issued new awards to fund ‘pan-coronavirus’ vaccines
On Sept. 28, 2021, the National Institute of Allergy and Infectious Diseases announced it had awarded approximately $36.3…
Pfizer started global phase 2/3 EPIC-PEP study of novel COVID-19 oral antiviral candidate for post-exposure prophylaxis in adults
On Sept. 27, 2021, Pfizer announced the start of the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for…
Relief reported that collaboration partner announced improved survival in highly comorbid COVID-19 patients treated with ZYESAMITM
On Sept. 27, 2021, RELIEF THERAPEUTICS reported its U.S. collaboration partner, NRx Pharmaceuticals, had announced top line data…
Pfizer announced Study of mRNA-based next generation flu vaccine program
On Sept. 27, 2021, Pfizer announced that the first participants have been dosed in a Phase 1 clinical…
Moderna announced supply agreement with Peru for 20 million doses of Its COVID-19 vaccine
On Sept. 24, 2021, Moderna announced a supply agreement with the government of Peru for 20 million doses…
Agriculture | Biotechnology | COVID-19 | Infectious Disease | USDA | Vaccine | Veterinary
USDA confirmed COVID-19 in Ferret in Florida
On Sept. 24, 2021, the U.S. Department of Agriculture’s (USDA) announced confirmation of SARS-CoV-2 in a ferret in…
Twist Bioscience single domain antibody TB202-3 showed potent binding to multiple strains of SARS-CoV-2
On Sept. 23, 2021, Twist Bioscience reported that its internally-discovered antibody candidate TB202-3 (CoVIC-094), demonstrated potent binding to…
Pfizer and BioNTech received first U.S. FDA Emergency Use Authorization of a COVID-19 vaccine booster
On Sept. 23, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) has authorized…
Results from Novavax NanoFlu influenza vaccine phase 3 clinical trial Published in The Lancet Infectious Diseases
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
Novavax and Serum Institute announced submission to WHO for Emergency Use Listing of COVID-19 vaccine
On Sept. 23, 2021, Novavax with its partner, Serum Institute of India announced a regulatory submission to the…
OraSure received $13.6 million from BARDA to support InteliSwab COVID-19 rapid test 510(k) Clearance and CLIA Waiver
On Sept. 23, 2021, OraSure Technologies and the Biomedical Advanced Research Development Authority (BARDA) announced up to $13.6…
Tonix Pharmaceuticals expanded research collaboration to develop precision medicine techniques for COVID-19 vaccines and therapeutics
On Sept. 23, 2021, Tonix Pharmaceuticals announced it had expanded its research collaboration with Columbia University. The research…
INOVIO received regulatory authorization to conduct phase 3 efficacy trial of COVID-19 DNA vaccine candidate in Mexico
On Sept. 22, 2021, Inovio Pharmaceuticals announced that it had received authorization from COFEPRIS, the national health regulatory…
Pfizer and BioNTech expanded U.S. collaboration to provide 500 million additional COVID-19 vaccine doses to poorest countries
On Sept. 22, 2021, Pfizer and BioNTech announced plans to expand their agreement with the U.S. government by…